TY - JOUR
T1 - 2018 Kidney Disease
T2 - Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report
AU - Li, Philip Kam Tao
AU - Bavanandan, Sunita
AU - Mohamed, Rosmawati
AU - Szeto, Cheuk Chun
AU - Wong, Vincent Wai Sun
AU - Chow, Kai Ming
AU - Dan, Yock Young
AU - Huang, Chiu Ching
AU - Lai, Ching Lung
AU - Tanwandee, Tawesak
AU - Teo, Boon Wee
AU - Wong, Grace Lai Hung
AU - Yeoh, Eng Kiong
AU - Iseki, Kunitoshi
AU - Leung, Chi Bon
AU - Park, Hyeong Cheon
AU - Kanjanabuch, Talerngsak
AU - Lu, Wanhong
AU - Fung, James
AU - Jia, Jidong
AU - Kanda, Eiichiro
AU - Law, Man Ching
AU - Liu, Hong
AU - Loo, Ching Kong
AU - Mak, Siu Ka
AU - Lui, Sing Leung
AU - Tang, Hon Lok
AU - Wang, Angela Yee Moon
AU - Yu, Ming Lung
AU - Cheung, Michael
AU - Jadoul, Michel
N1 - Publisher Copyright:
© 2020 International Society of Nephrology
PY - 2020/8
Y1 - 2020/8
N2 - In 2018, Kidney Disease: Improving Global Outcomes (KDIGO) published a clinical practice guideline on the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in chronic kidney disease (CKD). The guideline synthesized recent advances, especially in HCV therapeutics and diagnostics, and provided clinical recommendations and suggestions to aid healthcare providers and improve care for CKD patients with HCV. To gain insight into the extent that the 2018 guideline has been adopted in Asia, KDIGO convened an HCV Implementation Summit in Hong Kong. Participants included nephrologists, hepatologists, and nurse consultants from 8 Southeast Asian countries or regions with comparable high-to-middle economic ranking by the World Bank: mainland China, Hong Kong, Japan, Malaysia, Singapore, South Korea, Taiwan, and Thailand. Through presentations and discussions, meeting participants described regional practice patterns related to the KDIGO HCV in CKD guideline, identified barriers to implementing the guideline, and developed strategies for overcoming the barriers in Asia and around the world.
AB - In 2018, Kidney Disease: Improving Global Outcomes (KDIGO) published a clinical practice guideline on the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in chronic kidney disease (CKD). The guideline synthesized recent advances, especially in HCV therapeutics and diagnostics, and provided clinical recommendations and suggestions to aid healthcare providers and improve care for CKD patients with HCV. To gain insight into the extent that the 2018 guideline has been adopted in Asia, KDIGO convened an HCV Implementation Summit in Hong Kong. Participants included nephrologists, hepatologists, and nurse consultants from 8 Southeast Asian countries or regions with comparable high-to-middle economic ranking by the World Bank: mainland China, Hong Kong, Japan, Malaysia, Singapore, South Korea, Taiwan, and Thailand. Through presentations and discussions, meeting participants described regional practice patterns related to the KDIGO HCV in CKD guideline, identified barriers to implementing the guideline, and developed strategies for overcoming the barriers in Asia and around the world.
KW - chronic kidney disease
KW - dialysis
KW - direct-acting antiviral
KW - infection control
KW - kidney transplantation
UR - http://www.scopus.com/inward/record.url?scp=85088255142&partnerID=8YFLogxK
U2 - 10.1016/j.ekir.2020.05.001
DO - 10.1016/j.ekir.2020.05.001
M3 - 文章
AN - SCOPUS:85088255142
SN - 2468-0249
VL - 5
SP - 1129
EP - 1138
JO - Kidney International Reports
JF - Kidney International Reports
IS - 8
ER -
